Work

Patients (Pts) with Ph+ Chronic Myeloid Leukemia In Chronic Phase (CML-CP) with a Suboptimal Molecular Response to Imatinib (IM) Can Achieve Deeper Responses When Switched to Nilotinib

Year: 2010

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v116.21.2301.2301

Authors: Carole Miller, Sikander Ailawadhi, Anand P. Jillella, Jerald P. Radich, Daniel J DeAngelo, Stuart L Goldberg, Denise Williams, Felice P. Lin, Luke Paul Akard

Institutions: Saint Agnes Hospital, University of Southern California, Augusta University, Fred Hutch Cancer Center, Dana-Farber Cancer Institute, Hackensack University Medical Center, Novartis (United States)

Language: English

Topic: Chronic Myeloid Leukemia Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2549850818

FWCI: 0.198

Cites:

Cited by: 1

Related to: 10